FDA allows Houston cancer doctor to resume drug trial

Federal regulators have lifted a partial hold on a clinical trial performed by Stanislaw

Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997–2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR) - eClinicalMedicine

UTHealth Houston

Texas Medical Board sanctions controversial cancer doctor Burzynski

Helping cancer patients navigate CAR T cell therapy

Doctor claims to cure pediatric cancer, critics skeptical

FDA gives controversial doc green light to restart work

Doctor claims to cure pediatric cancer, critics skeptical

At the Bedside: Pancreatic cancer patient 'back on track' after UTHealth Houston clinical trial therapy shrinks tumor - UTHealth Houston

The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019 - The Lancet Oncology

Katy Rezvani MD Anderson Cancer Center

Ashish M. Kamat MD Anderson Cancer Center

Recent Targeted Therapies Approved for the Treatment of Patients with Urothelial Carcinoma

Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems